Year All202520242023202220212020201920182017 Inozyme Pharma Receives Orphan Drug Designation for INZ-701 in the United States and European Union Jul 17, 2018 Inozyme Pharma Offers No-Cost Genetic Testing for Rare Calcification Disorders Jun 13, 2018 Inozyme Pharma Appoints David Thompson, Ph.D. as Senior Vice President and Chief Scientific Officer May 01, 2018 Inozyme Pharma Raises $49 Million in a Series A Financing to Develop Therapies for Rare Diseases Affecting Soft Tissues and Bone Nov 15, 2017
Year All202520242023202220212020201920182017 Inozyme Pharma Receives Orphan Drug Designation for INZ-701 in the United States and European Union Jul 17, 2018 Inozyme Pharma Offers No-Cost Genetic Testing for Rare Calcification Disorders Jun 13, 2018 Inozyme Pharma Appoints David Thompson, Ph.D. as Senior Vice President and Chief Scientific Officer May 01, 2018 Inozyme Pharma Raises $49 Million in a Series A Financing to Develop Therapies for Rare Diseases Affecting Soft Tissues and Bone Nov 15, 2017
Inozyme Pharma Receives Orphan Drug Designation for INZ-701 in the United States and European Union Jul 17, 2018
Inozyme Pharma Appoints David Thompson, Ph.D. as Senior Vice President and Chief Scientific Officer May 01, 2018
Inozyme Pharma Raises $49 Million in a Series A Financing to Develop Therapies for Rare Diseases Affecting Soft Tissues and Bone Nov 15, 2017